Receiving nocturnal dialysis may decrease the risk of heart disease in patients with end-stage renal disease.
An overview of how data from the Centers for Medicare & Medicaid Services' CROWNWeb system could provide additional support.
Behavioral therapy provided chair-side to kidney failure patients while they are undergoing dialysis may help fight depression.
Novel assay can distinguish between oxidized and nonoxidized forms of parathyroid hormone.
Agency releases a video, a poster, and a pocket guide to help providers and patients prevent development of infectious complications in patients undergoing hemodialysis.
Decreasing TSAT and higher ESA doses are associated with increasing platelet counts.
Declines in serum phosphorus over time may improve survival.
Worsening or resistant hyperphosphatemia may be an under-appreciated consequence of secondary hyperparathyroidism.
Atorvastatin did not reduce the risk of a combined endpoint of cardiovascular death, MI, and stroke.
Levels declined significantly from 7.2 to 5.0 mg/dL, data show.
Researchers speculate patients on peritoneal dialysis are more physically active than those on HD, and this may lower diabetes risk.
These include use of lower ESA doses and hemoglobin levels.
Patients with levels below 10 g/dL had the highest unadjusted mortality and all-cause hospitalization rates.
Results show an increased risk of mortality and hospitalizations compared with late starts.
Study of patients new to dialysis also demonstrates an increase in the likelihood of hospitalization.
Low phosphorus increases all-cause and cardiovascular mortality only among the elderly.
Changes in body weight in advance of dialysis initiation are associated with significantly increased one-year mortality among nursing home residents.
Each 10 cc increment in epicardial adipose tissue is associated with a significant 6% increased risk of death in patients newly started on hemodialysis.